Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging

M. Guttinger, F. Guidi, M. Chinol, E. Reali, F. Veglia, G. Viale, G. Paganelli, A. Corti, A. G. Siccardi

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

We have shown previously that T cells, tagged with biotinylated anti-CD3 antibody fragments, can exert avidin-dependent cytolytic activity on suitably biotinylated tumor cells in vitro. In this study, we demonstrate that avidin-driven CTL-tumor bridging in vivo leads to growth inhibition of murine tumors WEHI-164 fibrosarcoma and RMA lymphoma. The biodistribution of biotin-tagged 111In-labeled T cells demonstrated a selective avidin-dependent and time-dependent accumulation of radioactivity at tumor sites. The specificity of lymphocyte tumor localization was demonstrated by the concurrent time-dependent decrease of radioactivity in the blood and in all other organs. Furthermore, we documented a therapeutic effect of the adoptively transferred T cells, i.e., a significant delay of tumor growth at early stages. All of the experiments included a control group of mice, which received all of the reagents, except avidin. These avidin-minus mice showed no specific localization and no delay in tumor growth, indicating that avidin bridging was essential for T-cell activity at tumor sites.

Original languageEnglish
Pages (from-to)4211-4215
Number of pages5
JournalCancer Research
Volume60
Issue number15
Publication statusPublished - 2000

Fingerprint

Adoptive Immunotherapy
Avidin
Cytotoxic T-Lymphocytes
Neoplasms
T-Lymphocytes
Radioactivity
Growth
Immunoglobulin Fragments
Fibrosarcoma
Therapeutic Uses
Biotin
Anti-Idiotypic Antibodies
Lymphoma
Lymphocytes
Control Groups

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Guttinger, M., Guidi, F., Chinol, M., Reali, E., Veglia, F., Viale, G., ... Siccardi, A. G. (2000). Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging. Cancer Research, 60(15), 4211-4215.

Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging. / Guttinger, M.; Guidi, F.; Chinol, M.; Reali, E.; Veglia, F.; Viale, G.; Paganelli, G.; Corti, A.; Siccardi, A. G.

In: Cancer Research, Vol. 60, No. 15, 2000, p. 4211-4215.

Research output: Contribution to journalArticle

Guttinger, M, Guidi, F, Chinol, M, Reali, E, Veglia, F, Viale, G, Paganelli, G, Corti, A & Siccardi, AG 2000, 'Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging', Cancer Research, vol. 60, no. 15, pp. 4211-4215.
Guttinger, M. ; Guidi, F. ; Chinol, M. ; Reali, E. ; Veglia, F. ; Viale, G. ; Paganelli, G. ; Corti, A. ; Siccardi, A. G. / Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging. In: Cancer Research. 2000 ; Vol. 60, No. 15. pp. 4211-4215.
@article{cd902b2eeb8a4dc4a9866e5ef2e37410,
title = "Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging",
abstract = "We have shown previously that T cells, tagged with biotinylated anti-CD3 antibody fragments, can exert avidin-dependent cytolytic activity on suitably biotinylated tumor cells in vitro. In this study, we demonstrate that avidin-driven CTL-tumor bridging in vivo leads to growth inhibition of murine tumors WEHI-164 fibrosarcoma and RMA lymphoma. The biodistribution of biotin-tagged 111In-labeled T cells demonstrated a selective avidin-dependent and time-dependent accumulation of radioactivity at tumor sites. The specificity of lymphocyte tumor localization was demonstrated by the concurrent time-dependent decrease of radioactivity in the blood and in all other organs. Furthermore, we documented a therapeutic effect of the adoptively transferred T cells, i.e., a significant delay of tumor growth at early stages. All of the experiments included a control group of mice, which received all of the reagents, except avidin. These avidin-minus mice showed no specific localization and no delay in tumor growth, indicating that avidin bridging was essential for T-cell activity at tumor sites.",
author = "M. Guttinger and F. Guidi and M. Chinol and E. Reali and F. Veglia and G. Viale and G. Paganelli and A. Corti and Siccardi, {A. G.}",
year = "2000",
language = "English",
volume = "60",
pages = "4211--4215",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging

AU - Guttinger, M.

AU - Guidi, F.

AU - Chinol, M.

AU - Reali, E.

AU - Veglia, F.

AU - Viale, G.

AU - Paganelli, G.

AU - Corti, A.

AU - Siccardi, A. G.

PY - 2000

Y1 - 2000

N2 - We have shown previously that T cells, tagged with biotinylated anti-CD3 antibody fragments, can exert avidin-dependent cytolytic activity on suitably biotinylated tumor cells in vitro. In this study, we demonstrate that avidin-driven CTL-tumor bridging in vivo leads to growth inhibition of murine tumors WEHI-164 fibrosarcoma and RMA lymphoma. The biodistribution of biotin-tagged 111In-labeled T cells demonstrated a selective avidin-dependent and time-dependent accumulation of radioactivity at tumor sites. The specificity of lymphocyte tumor localization was demonstrated by the concurrent time-dependent decrease of radioactivity in the blood and in all other organs. Furthermore, we documented a therapeutic effect of the adoptively transferred T cells, i.e., a significant delay of tumor growth at early stages. All of the experiments included a control group of mice, which received all of the reagents, except avidin. These avidin-minus mice showed no specific localization and no delay in tumor growth, indicating that avidin bridging was essential for T-cell activity at tumor sites.

AB - We have shown previously that T cells, tagged with biotinylated anti-CD3 antibody fragments, can exert avidin-dependent cytolytic activity on suitably biotinylated tumor cells in vitro. In this study, we demonstrate that avidin-driven CTL-tumor bridging in vivo leads to growth inhibition of murine tumors WEHI-164 fibrosarcoma and RMA lymphoma. The biodistribution of biotin-tagged 111In-labeled T cells demonstrated a selective avidin-dependent and time-dependent accumulation of radioactivity at tumor sites. The specificity of lymphocyte tumor localization was demonstrated by the concurrent time-dependent decrease of radioactivity in the blood and in all other organs. Furthermore, we documented a therapeutic effect of the adoptively transferred T cells, i.e., a significant delay of tumor growth at early stages. All of the experiments included a control group of mice, which received all of the reagents, except avidin. These avidin-minus mice showed no specific localization and no delay in tumor growth, indicating that avidin bridging was essential for T-cell activity at tumor sites.

UR - http://www.scopus.com/inward/record.url?scp=0033870884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033870884&partnerID=8YFLogxK

M3 - Article

C2 - 10945632

AN - SCOPUS:0033870884

VL - 60

SP - 4211

EP - 4215

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 15

ER -